Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Main|Search|PHGKB
Search PHGKB:

Last Posted: Nov 14, 2023
spot light Highlights

An AI-Enhanced Electronic Health Record Could Boost Primary Care Productivity.
Jeffrey E Harris et al. JAMA 2023 8

More than a few commentators have seriously inquired whether artificial intelligence (AI) could ultimately replace many clinicians. The far likelier prospect, however, is that the newly emerging technology will enhance clinical productivity. To be sure, AI-based pattern recognition software can already scan retinal photos for complications of diabetes, detect tuberculosis on chest x-rays, and evaluate screening mammograms. And some AI applications have been found to be comparable if not superior to human clinical judgment.

A new class of antibiotics delivers promising trial results against tuberculosis.
Carvalho Thiago et al. Nature medicine 2022 11

Nature Medicine explores the latest translational and clinical research news, with a clinical trial of a tRNA synthetase inhibitor for tuberculosis. The molecule functions as an inhibitor of the Mycobacterium tuberculosis enzyme leucyl-tRNA synthetase, blocking protein synthesis. Patients with drug-susceptible pulmonary tuberculosis treated with the investigational drug for 14 days showed a significant, dose-dependent reduction in colony-forming units in their sputum, the trial’s primary endpoint.

The science events to watch for in 2023 Moon landings, mRNA vaccines and climate finance are among the developments set to shape research in the coming year.
M Naddaf et al, Nature, December 19, 2022

Following the successful deployment of mRNA vaccines during the COVID-19 pandemic, a host of them are in development. BioNTech in Mainz, Germany, is expected to initiate first-in-human trials for mRNA vaccines against malaria, tuberculosis and genital herpes in the coming weeks. BioNTech is also collaborating with Pfizer, based in New York City, to trial an mRNA-based vaccine candidate to reduce the rate of shingles. Moderna in Cambridge, Massachusetts, also has mRNA vaccine candidates for the viruses that cause genital herpes and shingles.


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP